Dublin, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/2hqvvj/malignant) has announced the addition of the "Malignant Melanoma Pricing and Reimbursement" report to their offering.
With several new high cost melanoma drugs available, payer decisions on whether patients can access those drugs and under what conditions are becoming more important than ever. This report covers both analysis of past payer decisions and forward looking views based on payer interviews.
Key findings
- Prices of melanoma therapies and oncology drugs on the whole have become subject to closer scrutiny due to their high costs
- US payers have few tools for the utilization management of melanoma medicines due to limited treatment options
- Yervoy, Zelboraf, and Tafinlar fared well in health technology assessments in France and Germany, but have had limited uptake in more cost conservative markets due to their high costs
Key Topics Covered:
1. Executive Summary
2. Market Context
- Market entry of new drugs will dramatically increase the budget impact of melanoma treatments
- Marketed malignant melanoma products in the US, Japan, and five major EU markets
- Pipeline malignant melanoma treatments in late-stage development
- Price assumptions
- Bibliography
3. US
- Pricing
- Reimbursement
- Bibliography
4. Japan
- Successful pricing outcomes hinge on receipt of a pricing premium
- Nivolumab was awarded a 60% innovation margin
- Bibliography
5. Five Major EU Markets
- Pricing
- Reimbursement and health technology assessment
- Bibliography
For more information visit http://www.researchandmarkets.com/research/2hqvvj/malignant
Malignant Melanoma Pricing and Reimbursement Report - Melanoma Therapies and Oncology Drugs Prices have Become Subject to Closer Scrutiny Due to their High Costs
| Source: Research and Markets